Ya X. Wang
Changsha, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.
Journal: Nature medicine
Published: July 22, 2025
Association of Ion Concentration with Immune-Related Adverse Events and Prognosis in Lung Cancer Patients Treated with PD-1/PD-L1 Inhibitors.
Journal: Journal of Cancer
Published: June 30, 2025
First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer.
Journal: Med (New York, N.Y.)
Published: July 23, 2023
NPAS2 dampens chemo-sensitivity of lung adenocarcinoma cells by enhancing DNA damage repair.
Journal: Cell death & disease
Published: March 23, 2023
N6-Methyladenosine RNA Modification Landscape in the Occurrence and Recurrence of Nasopharyngeal Carcinoma.
Journal: World journal of oncology
Published: May 19, 2022
Profilin 1 Induces Tumor Metastasis by Promoting Microvesicle Secretion Through the ROCK 1/p-MLC Pathway in Non-Small Cell Lung Cancer.
Journal: Frontiers in pharmacology
Published: March 07, 2022
Downregulation of Profilin-1 Expression Attenuates Cardiomyocytes Hypertrophy and Apoptosis Induced by Advanced Glycation End Products in H9c2 Cells.
Journal: BioMed research international
Published: June 15, 2017
Profilin‑1 contributes to cardiac injury induced by advanced glycation end‑products in rats.
Journal: Molecular medicine reports
Published: September 24, 2016
Y-27632 reduces the MMP2 and MMP9 expression in endothelial cell via inhibition of ROCK signal pathway
Journal: Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Published: July 05, 2016
Showing 1-10 of 10
Last Updated: 09/26/2026